Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6042)	10/14/1998 6:02:00 PM
From: MARK C.	Read Replies (2) \| Respond to of 9523

Anthony, Page 12 - 1997 annual report: Pfizer expects to add to it's cardiovascular portfolio with regulatory filings in early 1998 for dofetilide ( tikosyn), a new treatment for atrial fibrillation (af). More than 10 million patients worldwide suffer from AF. Because AF can lead to the formation of blood clots, patients with AF run a fivefold increased risk of stroke. Symptoms of AF include chronic fatigue, palpitations, anxiety, shortness of breath, and poor exercise tolerance. Treatment cost for AF in the United States alone amount to nearly $8 billion. Dofelitide is the first medicine that specifically targets AF.It blocks the outflow of potassium in one, and only one, ion channel in the heart, thereby delaying the heart's refractory period and reducing the opportunity for arrhythmias. In a large, well-controlled U.S. clinical trial, two thirds of atrial fibrillation patients maintained on treatment with dofelitide remained in normal cardiac rhythm for a full year compared with only one quarter of patients treated with placebo. As a result, the product relieves the debilitating symptoms of AF and improves patients overall quality of life. Because of it's exquisite selectivity, dofelitide does not affect heart rate or depress cardiac pump function, and it possesses a very good toleration profile. On page 27 of the same report it shows Tikosyn as already being under regulatory review. Therefore I have to assume they filed very early this year. Hope this helps. MarkC.